'Emerging therapies and challenges for individuals with Angelman syndrome': Erratum

Abstract

Reports an error in 'Emerging Therapies and challenges for individuals with Angelman syndrome' by Helen S. Heussler (Current Opinion in Psychiatry, 2021[Mar], Vol 34[2], 123-128). The original review article may have misunderstood the findings and conclusions of recent EEG work by Frohlich and colleagues. The discrepancies are explained in this erratum. (The following abstract of the original article appeared in record [rid]2021-58022-009[/rid]). Purpose of review: This review describes current understandings in the search for therapies to support children with Angelman syndrome. There is a rapid progression in particular in genetic therapies in this disorder supported by the Angelman community. Recent findings: Recent papers shed light on the timing of therapies and novel genetic therapies coming to trial as well as potential therapies still in preclinical phases. Further understanding of UBE3A and its role in neuronal development and plasticity as well as other mechanisms contributing to the Angelman phenotype is offering an opportunity for novel therapeutics. Summary: Greater understanding of the pathophysiology of the different phenotypes will offer an opportunity for novel therapeutics and may well change the course of this disorder over time where previously there has been minimal ability to intervene. (PsycInfo Database Record (c) 2022 APA, all rights reserved)Child Development Program, Children’s Health Queensland, University of Queensland, Brisbane, QLD, Australia. Release Date: 20220609. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Erratum/Correction. Language: EnglishMajor Descriptor: Biological Markers; Epilepsy; Genetics; Phenotypes; Syndromes. Minor Descriptor: Neural Development; Pathophysiology. Classification: Neurological Disorders & Brain Damage (3297). References Available: Y. Page Count: 1. Issue Publication Date: Sep, 2021. Copyright Statement: All rights reserved. Wolters Kluwer Health, Inc. 2021. <br />